Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas

Table 3 Univariate and multivariate analyses of prognostic parameters for survival in the cohort patients with gastric neuroendocrine carcinomas

Prognostic parameter	Univariate			Multivariate
	HR	95%CI	P-value	HR	95%CI	P-value
Age (yr)
< 60	1.0 (Reference)
≥ 60	2.718	0.921-8.023	0.07
Gender
Male	1.0 (Reference)
Female	0.915	0.308-2.718	0.873
Tumor location
Cardia	1.0 (Reference)
Corpus	3.034	1.100-8.374	0.032	2.878	0.971-8.529	0.057
Antrum	2.331	0.817-6.648	0.114	2.51	0.285-22.125	0.407
Residual stomach anastomosis	1.401	0.176-11.159	0.75	1.373	0.399-4.718	0.615
Tumor size
≤ 5 cm	1.0 (Reference)
> 5 cm	1.605	0.693-3.717	0.269
T classification
T1/2	1.0 (Reference)
T3/4	0.76	0.407-1.420	0.39
Lymph node metastasis
Absent	1.0 (Reference)
Present	1.976	0.731-5.342	0.179
Liver metastasis
Absent	1.0 (Reference)
Present	3.515	1.269-9.731	0.016	4.045	1.140-14.351	0.031
CD8
Low	1.0 (Reference)
High	0.46	0.197-1.074	0.073
FOXP3
Low	1.0 (Reference)
High	1.375	0.593-3.186	0.458
PD-1
Low	1.0 (Reference)
High	0.954	0.420-2.167	0.91
PD-L1
Low	1.0 (Reference)
High	2.846	1.170-6.922	0.021	3.646	1.372-9.688	0.009

PD-L1: Programmed death ligand 1; PD-1: Programmed death 1. HR: Hazard ratio; CI: Confidence interval.